Dasatinib is a multi-kinase inhibitor in clinical trials for glioma, and thus far failed to demonstrate significant efficacy. We investigated whether the ABC efflux transporters, ABCG2 and ABCB1, expressed in the blood-brain barrier (BBB), are limiting the efficacy of dasatinib in the treatment of glioma using genetic and pharmacological approaches. We utilized a genetic brainstem glioma mouse model driven by platelet-derived growth factor-B and p53 loss using abcg2/abcb1 wild type (ABC WT) or abcg2/abcb1 knockout mice (ABC KO). 
INTRODUCTION:
Brain stem glioma, also known as diffuse intrinsic pontine glioma (DIPG), is a rare and incurable brain tumor with poor survival rates due to lack of effective therapeutic options (1-3). DIPG predominantly arises in children and accounts for about 15-20% of all pediatric brain tumors (1). It is the leading cause of death for patients with pediatric brain tumors; the median survival is less than one year, and less than 10% of children survive more than 2 years after diagnosis (1, 2, 4).
This poor prognosis has remained unchanged over the past 30 years (1, 4). The infiltrative nature and anatomical location of this disease make surgical resection impossible (4) . Conventional radiation therapy has remained the standard of care providing only temporary improvement and no chemotherapy or targeted agent has demonstrated a survival benefit (2) (3) (4) . Therefore, there is an urgent need for the development of effective strategies to treat this devastating disease.
Until recently, knowledge concerning the molecular biology of DIPG was limited due to lack of availability of tumor tissue (4) . However, in recent years, there has been a paradigm shift toward obtaining DIPG tissue, which has resulted in improved understanding of DIPG tumor biology. These studies have demonstrated that DIPGs harbor both genetic alterations common to gliomas that arise in other parts of the central nervous system, including adult gliomas, as well as unique genetic alterations, such as gain of function histone mutation, K27M, in H3.1 or H3.3 and activating mutations in ACVR1 (5) (6) (7) (8) (9) (10) . With regards to receptor tyrosine kinase (RTK) signaling, platelet derived growth factor (PDGF) signaling, in particular PDGFRA, is thought to play a role in brainstem gliomagenesis as multiple studies indicate that approximately 30% of human DIPGs harbor gain or amplification in PDGFRA (11) (12) (13) (14) (15) . Dasatinib, a multi-kinase inhibitor that inhibits PDGFRA and SRC among others has recently been demonstrated to have antitumor activity in vitro in 4 DIPG cell-lines (16) . By contrast, dasatinib has recently been evaluated in a clinical trial for children with DIPG with disappointing results, citing only limited efficacy of the drug (3) . Evaluation of the cerebral spinal fluid (CSF) of two patients suggested insufficient drug delivery as a potential mechanism of resistance, although CSF is not a good surrogate for brain penetration for a drug like dasatinib, a substrate of both ABCB1 (also known as P-glycoprotein, P-gp or MDR) and ABCG2 (also known as BCRP)) (3, 17) . With this perspective, we sought to evaluate the efficacy of dasatinib in a geneticallyengineered mouse model of brainstem glioma driven by PDGF-B signaling (18, 19) .
One of the major hurdles in the treatment of brain related disorders is the delivery of therapeutic agents across the blood-brain-barrier (BBB). The BBB, formed by capillary endothelial cells joined together by tight junction proteins, limits the paracellular movement of large molecules (20) . While tight junctions present a physical barrier to the drugs, efflux transporter proteins found within the brain primarily on endothelial cells, such as ABCB1 and ABCG2 present an additional functional barrier by pumping drugs back into blood circulation (21) . Recent studies have shown that several molecularly-targeted agents, including dasatinib, are substrates of ABCB1 and ABCG2 and as such have limited brain distribution (21) (22) (23) (24) (25) (26) . One potential strategy to improve delivery of substrate drugs across the BBB is simultaneous inhibition of these efflux transporters. Elacridar is a potent inhibitor of both ABCB1 and ABCG2 and co-administration of elacridar with molecularly-targeted agents results in improved brain distribution (24, 26, 27) .
However, the use of elacridar in preclinical setting for chronic administration is limited by its poor oral absorption and lack of injectable formulations (27) (28) (29) .
Recently, we reported a novel microemulsion formulation of elacridar, which has improved bioavailability and can be used for chronic administration in preclinical models (29) .
Given the feasibility of chronic administration of elacridar in the microemulsion formulation, and the current ongoing clinical trials with dasatinib in childhood high-grade gliomas including DIPG, the aim of the current study was to evaluate the efficacy of dasatinib alone and in combination with the novel microemulsion formulation of elacridar in a preclinical model of brainstem glioma. We hypothesized that dasatinib delivery would be significantly improved by coadministration with the elacridar microemulsion formulation, ultimately resulting in improved efficacy. Using a PDGF-B driven brainstem glioma model, we showed that genetic deletion of ABCB1 and ABCG2 or treatment with elacridar significantly enhances the efficacy of dasatinib. Surprisingly, the observed increased efficacy of elacridar in combination with dasatinib relative to dasatinib alone was not due to improved drug delivery to the tumor core. Furthermore, elacridar treatment significantly enhances the cytotoxicity of dasatinib of both ABC WT and ABC KO brainstem glioma cell-lines suggesting an ABCB1/ABCG2 independent mechanism for elacridar. Our data provide a preclinical foundation for future trials using this novel combination (elacridar microemulsion with dasatinib) in the hopes of improving survival for children suffering from this devastating disease. The generations were kept similar between the two models (to maintain the same genetic mixtures between the two models). For genotyping, tail DNA was obtained using tissue-DNA-extraction kit XNAT (Sigma-Aldrich) according to the manufacturer's instructions. All work with mice was done in accordance with the Duke University Animal Care and Use Committee and the Guide for the Care and Use of Laboratory Animals.
MATERIALS AND METHODS

Chemicals
DF1 cell culture and generation of PDGF-B-induced glioma in ABC KO and ABC WT mice
DF1 cells were cultured and transfected with RCAS-PDGF-B and RCAS-Cre plasmids as previously described (18) . Combination of viruses at a 1:1 ratio was injected to generate in vivo brainstem glioma as previously described (18) .
Injected mice were monitored daily for symptoms and euthanized with CO 2 upon observing sure signs of brain tumors (enlarged head, ataxia, lethargic, weight loss up to 25%) or 16 weeks post-injection in the absence of symptoms.
Histological evaluation of tumor bearing ABC WT and ABC KO mice
We induced tumors in ABC WT (n = 20) and KO (n = 15) mice as described above using RCAS-PDGF-B and RCAS-Cre. Mice were sacrificed when they reached euthanasia criteria as described above or at the 16-week endpoint without presentation of symptoms. Brain tissues were removed and fixed in 10% formalin followed by paraffin embedding, and sectioning at a thickness of 5 µm The composition of microemulsion used in this study was as previously described (29) . Treatments began 28 days after injection of tumor-initiating viruses at a time-point where tumors are already present but mice are asymptomatic (19) . 
BBB integrity in brainstem glioma
Tumor-bearing ABC WT and ABC KO mice (n = 10 per group) were injected with TRD (1.5 mg/animal body weight) via tail vein. Ten minutes post-injection of TRD, each animal was perfused by a brief cardiac washout for 30 seconds using 1x DPBS (Gibco, 14190-144) (30) . After perfusion, the tumor tissue in the brainstem was isolated from normal tissue in the cortex and was separately snap frozen and stored at -80°C. For analysis, the tissue samples were thawed to room temperature and homogenized with 3 volumes of deionized water. The TRD concentrations in total tissue homogenates were determined using BioteK plate reader. Briefly, a stock solution (1 mg/mL) of TRD was prepared by dissolving 1 mg of TRD in 1 mL of DI water. In vitro cell viability assays with dasatinib ± elacridar Cells (10000/well) were plated in a 96-well plate for 24h before drug treatment.
After 24 hours, cells were exposed to dasatinib at various concentrations with or without 5μM elacridar for 72h. Cell viability was measured by CellTiter-Glo (Promega). The dose-response curves were generated with Prism software and analyzed using nonlinear regression. The values of half-maximal inhibitory concentration (IC50) were calculated by using log (agonist) vs. response including variable slope (four parameters) statistics and normalized in GraphPad Prism.
Quantitative RT-PCR
Total RNA was isolated from ABC KO or ABC WT tumor neurospheres or brainstem nestin progenitors sorted from nestin-CFPnuc mice (32) using the RNeasy Kit Qiagen (Maryland, USA). The RNA was quantified in a Nanodrop 
Statistical analysis
Survival curves were compared using Mantel-Cox (Log-Rank) statistical analysis. The significant differences of CC3 levels, TRD levels, and dasatinib distribution were determined by Mann-Whitney statistical test.
RESULTS:
Absence of abcg2 and abcb1 significantly increases tumor latency
We observed a significant difference in the tumor latency between ABC KO and ABC WT mice (47 days for ABC KO mice, n = 15 vs. 34 days for ABC WT mice, n = 20; p = 0.006; Figure 1A ). However, the tumor incidence in both ABC KO and ABC WT models was the same (80%). Incidence of grade IV gliomas (40% vs. 60%, p=0.31 fisher's exact test), grade III gliomas (33% vs. 15%, p=0.25 fisher's exact test), and grade II gliomas (7% vs. 5% p=1.0 fisher's exact test) was not significantly different between ABC KO and ABC WT tumor models, respectively. ABC KO and ABC WT tumors were characterized as gliomas by staining for H&E, Nestin, Olig2, and phospho-H3 ( Figure 1B) . Thus, these data show that absence of abcg2 and abcb1 increases tumor latency without affecting tumor incidence or grade and without significantly impacting the level of nestin, olig2, or phospho-H3 expression. The mechanism for how abcg2 and abcb1 may impact tumor latency is unknown. As this model arises in nestin-expressing progenitors residing in the neonatal brainstem, we examined abcg2 and abcb1 (Figures S3 and S4) . Despite the intra-tumor and inter-tumor heterogeneity, there was greater CC3 staining in ABC KO mouse tumors treated with dasatinib as compared to any other group (Figure 2A and 2B) . The levels of CC3 staining were quantified using MetaMorph software by measuring the CC3-positive pixels per high-powered field normalized to nuclear area. The mean CC3-positive pixels per nuclear area in ABC KO mice treated with dasatinib (0.47) was significantly greater than both ABC WT mice treated with dasatinib (0.23, p-value = 0.015; Figure 2C ) and ABC KO mice treated with vehicle (0.067, p-value = 0.0044; Figure 2C ). There was a significant difference in CC3 levels between ABC WT mice treated with dasatinib and ABC WT mice treated with vehicle (0.054, p-value = 0.020; Figure 2C ).
Because we observed significantly greater CC3 immunostaining in tumor-bearing ABC KO mice treated with dasatinib relative to tumor-bearing ABC WT mice treated with dasatinib, these results suggest that ABCB1 and ABCG2 may influence the anti-tumor activity of dasatinib in the PDGF-B driven brainstem glioma mouse model.
Dasatinib significantly prolongs survival in ABC KO mice
To determine whether the increased apoptotic effect of dasatinib in the ABC KO model relative to the ABC WT model will translate to a survival benefit, tumor- Figure   3B ). Similar results were observed when the dasatinib levels in the tumor-bearing and non-tumor brain regions were normalized to the respective plasma concentrations (p-value = 0.18 and 0.004, respectively; Figure 3C ). These data suggest that the delivery of dasatinib is significantly improved to the normal brain regions but not to the tumor-bearing region in the absence of the ABCG2 and ABCB1 transporters. Figure 4C ). Thus elacridar co-administration does not significantly increase the delivery of dasatinib to the tumor-bearing region or normal brain in this PDGF-B driven brainstem glioma model. Important controls to these experiments were measurements of elacridar concentrations in the brains of ABC WT and ABC KO mice where we did not observe a significant difference ( Figure   S5 ) and measurements of dasatinib concentrations in ABC KO mice treated with dasatinib alone vs. dasatinib + elacridar levels where again we did not observe any significant differences ( Figure S6 ).
BBB integrity is compromised in brainstem glioma
In order to investigate the permeability of BBB in this brainstem glioma model, 
DISCUSSION:
DIPG is one of the leading causes of cancer related deaths in children (1). The failure of systemic chemotherapy or targeted agents in DIPG has been attributed to the inadequate delivery across the BBB (4, 23) . Therefore, there is an urgent need for effective therapies for this deadly tumor that take into account the issue of drug delivery. In the current study, we have tested a combination therapy of dasatinib with elacridar in a preclinical model of brainstem glioma driven by PDGF-B and p53 loss with the hypothesis that elacridar would increase the efficacy of dasatinib by increasing the brain and tumor distribution of dasatinib.
Our data demonstrate that the combination of dasatinib and elacridar does significantly improve the median survival in mice with brainstem glioma relative to dasatinib alone, however, the data also indicate this improvement may not be through increased drug delivery. It should be noted that in this study we did not measure dasatinib concentrations in different regions of the tumor. Measurement of dasatinib concentrations in tumor core and tumor rim would give some additional insights into regional delivery. Even though we observed no significant increase in dasatinib concentrations in the tumor, regional delivery might have had some influence in the resulted increased efficacy. However, measurement of regional dasatinib concentrations in this brainstem glioma model is an extremely difficult task, given its location and size. It remains to be determined exactly how elacridar increases the efficacy of dasatinib in this model. Previous studies have demonstrated that dasatinib is a dual substrate of ABCB1 and ABCG2 and that its normal brain distribution significantly increases in the absence of ABCB1 and ABCG2 (24, 39) . To test the pharmacodynamic effects of dasatinib in this brainstem glioma model induced in ABC KO mice relative to ABC WT mice, we evaluated levels of CC3, a marker of apoptosis, in ABC WT and ABC KO tumor tissue. Significantly higher CC3 staining was observed in ABC KO tumor sections as compared to ABC WT tumor sections. These data suggest that dasatinib is more cytotoxic in a glioma model induced in mice deficient for ABCG2 and ABCB1. 
To determine whether the increased cytotoxicity of dasatinib in the ABC KO model results in improved survival, we conducted a survival study, where tumorbearing ABC WT and ABC KO mice were treated with dasatinib. ABC KO mice treated with dasatinib had a significantly longer survival as compared to the ABC WT mice treated with dasatinib although a caveat of this comparison is that the ABC KO model inherently has significantly longer tumor latency. In separate animals, the normal brain concentrations of dasatinib were found to be significantly higher in ABC KO mice as compared to those found in ABC WT mice, which is in line with the published literature. Interestingly, tumor dasatinib concentrations were not significantly different in ABC KO mice as compared to those in ABC WT mice suggesting that drug delivery to the tumor may not be an explanation for the increased efficacy of dasatinib in the ABC KO mice.
Many studies have indicated that pharmacological inhibition of ABCB1 and ABCG2 with elacridar may overcome the inadequate drug delivery to the brain (40) (41) (42) . Until recently, chronic multidose regimens in preclinical setting were problematic because of poor bioavailability of elacridar (26, 43, 44) . Recent development of a microemulsion formulation of elacridar enabled us to test chronic administration of elacridar at clinically relevant doses either orally or intraperitoneally (29) . First, to determine whether elacridar in a microemulsion formulation in combination with dasatinib improves the survival of DIPG-bearing mice, tumor-bearing ABC WT mice were treated with either dasatinib alone or in combination with elacridar. It should be noted that this chronic dosing regimen of elacridar microemulsion was well tolerated, in contrast to prior studies (43) noteworthy to mention that the BBB remains relatively intact in the cortex of the tumor-bearing mice. Whether the BBB in this brainstem model is more compromised than in the human disease remains to be determined, as TRD measurements cannot be done in humans. Recently, we have used DCE MRI to evaluate the BBB in our brainstem glioma model and compared it to genetically identical gliomas induced in the cerebral cortex. Interestingly, we observed that the BBB in our brainstem glioma model is significantly less permeable than genetically identical gliomas induced in the cerebral cortex although some contrast enhancement in the brainstem gliomas was observed (50).
Lastly, it is worth noting that the PDGF-B; p53 deficient brainstem glioma model used in this study does not include the recently described K27M H3.3/3.1 histone mutations recently described in the majority of human DIPGs (5). In addition, although PDGF-B amplifications have been reported in DIPG, it is more common for the PDGFR-A receptor to be gained or amplified in DIPG (13) . As PDGF-B activates both PDGFRA and PDGFRB, the latter of which is present in the vasculature, this model may be particularly sensitive to angiogenesis inhibition. Therefore, the combination of dasatinib + elacridar should also be evaluated in DIPG xenograft models and in genetically engineered mouse models that also include the K27M H3.3/H3.1 mutations.
In summary, this study highlights the effect of elacridar on the efficacy of dasatinib in a preclinical model of brainstem glioma. Our data suggest that elacridar increases the efficacy of dasatinib in brainstem glioma without a significant increase in its delivery to the tumor and potentially through ABCB1 and ABCG2 independent mechanisms. Future studies need to investigate the mechanism behind the increased efficacy of dasatinib in the presence of elacridar microemulsion.
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